# Orikine Bio S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orikine-bio-s-l

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.orikine.bio
- Total disclosed funding: $6.1M
- Latest round: Seed (Jul 18, 2023)
- Investors on record: 2

## About

Based in Barcelona, Spain, and founded in 2022 by its CEO Alejo Chorny, and co-founders Luis Serrano Pubul, Javier Delgado, and Ariadna Montero, Orikine Bio S.L. is a spin-off from the Centre for Genomic Regulation (CRG) and operates as a biotech company focused on the treatment of immune-mediated diseases through the development of engineered cytokines. In December 2024, Orikine Bio S.L. raised EUR 800,000 million in grant funding led by new investor Ministerio de Ciencia, Innovación y Universidades.

Orikine Bio S.L. platform produces cytokines that are vital immune system proteins that act as soluble messengers, controlling various immune responses. The cytokine-based therapies target autoimmune and inflammatory diseases. Additionally, the company's platform's versatility allows the development of new drugs for a wide range of immune-based diseases.

The company plans to use the grant funding to support its research and development efforts for its ORK-1 project.

## Funding rounds

- Seed, Jul 18, 2023, $6.1M — AdBio Partners, Asabys Partners

## Investors

- AdBio Partners (https://capitalatlas.ai/funds/adbio-partners) — Seed
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Seed